Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Gustafson

Showing results (621-630 of 634) with videos related to

Pageof 64
Sort By:
Journal of Hepatology|October 3, 2021
ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLDKathleen E Corey, Rebecca Pitts, Michelle Lai, et al.
Cancer Research|July 26, 2018
Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal CancerAnuradha Krishnamurthy, Arvind Dasari, Anne M Noonan, et al.
Science Translational Medicine|February 5, 2016
Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative OncologyAmy K LeBlanc, Matthew Breen, Peter Choyke, et al.
Hepatology Communications|September 24, 2021
Distinct Hepatic Gene-Expression Patterns of NAFLD in Patients With ObesitySonu Subudhi, Hannah K Drescher, Laura E Dichtel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancerAnna Spreafico, John J Tentler, Todd M Pitts, et al.
Neuro-Oncology|July 24, 2023
EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progressionArthur R Wolin, Melanie Y Vincent, Taylor Hotz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2020
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid TumorsS Lindsey Davis, Anastasia A Ionkina, Stacey M Bagby, et al.
Cancer Research|April 29, 2020
Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and MetastasisHengbo Zhou, Melanie A Blevins, Jessica Y Hsu, et al.
Kidney International Reports|February 14, 2022
One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) TrialMeghan Elizabeth Sise, David Seth Goldberg, Douglas Earl Schaubel, et al.
The Lancet. Gastroenterology & Hepatology|July 30, 2019
Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label studyEmily D Bethea, Kerry Gaj, Jenna L Gustafson, et al.
Pageof 64

Showing results (621-630 of 634) with videos related to

Sort By:
Pageof 64
Journal of Hepatology|October 3, 2021
ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLDKathleen E Corey, Rebecca Pitts, Michelle Lai, et al.
Cancer Research|July 26, 2018
Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal CancerAnuradha Krishnamurthy, Arvind Dasari, Anne M Noonan, et al.
Science Translational Medicine|February 5, 2016
Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative OncologyAmy K LeBlanc, Matthew Breen, Peter Choyke, et al.
Hepatology Communications|September 24, 2021
Distinct Hepatic Gene-Expression Patterns of NAFLD in Patients With ObesitySonu Subudhi, Hannah K Drescher, Laura E Dichtel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancerAnna Spreafico, John J Tentler, Todd M Pitts, et al.
Neuro-Oncology|July 24, 2023
EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progressionArthur R Wolin, Melanie Y Vincent, Taylor Hotz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2020
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid TumorsS Lindsey Davis, Anastasia A Ionkina, Stacey M Bagby, et al.
Cancer Research|April 29, 2020
Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and MetastasisHengbo Zhou, Melanie A Blevins, Jessica Y Hsu, et al.
Kidney International Reports|February 14, 2022
One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) TrialMeghan Elizabeth Sise, David Seth Goldberg, Douglas Earl Schaubel, et al.
The Lancet. Gastroenterology & Hepatology|July 30, 2019
Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label studyEmily D Bethea, Kerry Gaj, Jenna L Gustafson, et al.
Pageof 64